{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026119","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.731898+00:00","generated_at":"2026-06-18T23:38:53.572133+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"uniQure reports FY2022 net loss of $126.8M; revenue drops to $106.5M from $524M","bullets":["Net loss of $126.8M ($2.71 loss per share) vs net income of $329.6M in 2021.","Revenue of $106.5M, down 80% YoY, primarily due to absence of large license revenue from CSL Behring transaction.","Cash and investments $392.8M as of Dec 31, 2022; expects funding into 2025 assuming $100M milestone from HEMGENIX first U.S. sale.","HEMGENIX received U.S. and EU marketing approvals for hemophilia B; eligible for $100M and $75M milestone payments from CSL Behring.","Pipeline: AMT-130 Huntington's update expected Q2 2023; AMT-162 (SOD1 ALS) and AMT-260 (epilepsy) Phase I/II trials expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026119","json":"https://secwatch.observer/filing/0001104659-23-026119.json","markdown":"https://secwatch.observer/filing/0001104659-23-026119.md","text":"https://secwatch.observer/filing/0001104659-23-026119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/0001104659-23-026119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/tm237999d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:38:53.572133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7fc01a5a1ca4bb0f0388fa386cb3b639d2a229f","claim":"uniQure N.V. reported financial results for the full year ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2022 and highlighting company progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/0001104659-23-026119-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}